Pfizer Official Rost in '60 Minutes' Interview Says He Supports Parallel Trading of Prescription Drugs
Main Category: Pharma Industry / Biotech IndustryArticle Date: 07 Jun 2005 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Peter Rost, vice president of marketing for Pfizer, in an interview on CBS'... "60 Minutes" on Sunday supported the practice of parallel trading -- a "tightly regulated" system of importing drugs between countries that has been used in Europe for more than 20 years. Although pharmaceutical companies in Europe -- where prescription drugs on average cost about half as much as those in the United States -- sell identical drugs to different countries at different prices, parallel trading allows drugs to be purchased in countries where they are less expensive, such as Spain, and sold at a discount in countries where they are more expensive, such as Denmark, according to Rost. CBS reports that parallel traded drugs may only be purchased from a licensed pharmacy -- not over the Internet. In addition, parallel trading companies only alter the medication's external packaging and are regularly inspected by their country's health authorities. "Clearly this is a matter of profits. It's not necessarily a matter of safety. ... It would be derogatory to claim that Americans would not be able to handle reimportation when the rest of the educated world can do this," Rost said. The "60 Minutes" segment also includes comments from U.S. Surgeon General Richard Carmona; Eric Pfeiffer, owner of the Danish parallel trading company Paranova; Uta Porksen, a Danish pharmacist who sells parallel traded drugs; and John Theriault, vice president of global security for Pfizer (Simon, "60 Minutes," CBS, 6/5).
Pfizer
"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/25731.php>
APA
http://www.medicalnewstoday.com/releases/25731.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



